The purpose of the current investigation is to demonstrate the efficacy of high-dose furosemide plus small-volume hypertonic saline solution and a Sodium-Glucose cotransporter-2 (SGLT-2) inhibitor among patients admitted for acute exacerbation of heart failure, in determining a significant increase in diuresis and natriuresis. It is also accompanied by a rapid reduction in body weight and a substantial decrease in hospitalization length without compromising renal function.
acute heart failure;
diabetes type 2.
low estimated glomerular filtration rate;
hypernatremia;
diabetes type 1;
non-cardiac causes of dyspnea;
Parallel
Dapagliflozin tablet
DrugDapagliflozin 10 mg 1 tablet once daily
Hypertonic Saline Solution, 1 Ml
DrugIntravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily
Furosemide Injection
DrugFurosemide 20 mg
Diuresis from the baseline and up to 1 week
Daily urinary volume (mL) are detected by chemiluminescence immunoassay.
Natriuresis from the baseline and up to 1 week
Daily natriuresis (mEq/L) are detected by chemiluminescence immunoassay.
Length of hospital stay
Duration of hospital stay in days.
Kidney function during treatment
Daily evaluation of creatinine (mg/dL).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
